High Potency Active Pharmaceutical Ingredients Market, By Molecule Type (Innovative, Generic), By Production Technology (Chemical Synthesis, Biotechnology), By Application (Oncology, Hormonal, Glaucoma, Others), and By Region (North America, Latin America

High Potency Active Pharmaceutical Ingredients Market, By Molecule Type (Innovative, Generic), By Production Technology (Chemical Synthesis, Biotechnology), By Application (Oncology, Hormonal, Glaucoma, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

High potency active pharmaceutical ingredients (HPAPIs) are small-molecule, biologic, or hybrids of antibody–drug conjugates, which link a cytotoxic small-molecule to a monoclonal antibody. Demand for high potency active pharmaceutical ingredients (HPAPIs) is rapidly increasing due to its ability to target diseased cells more precisely and selectively than other APIs and is regarded as a relatively more efficient treatment for cancer and chronic diseases such as diabetes and heart diseases, worldwide. According to estimates from the International Agency for Research on Cancer (IARC), in 2012, 14.1 million new cancer cases and 8.2 million cancer deaths were recorded worldwide. This global burden of cancer is expected to account for 21.7 million new cancer cases and cause 13 million deaths by 2030.
Restraints of the Global High Potency Active Pharmaceutical Ingredients Market
Major factors hampering the growth of the high potency active pharmaceutical ingredients market during the forecast period constitutes of high costs, and stringent regulations.
Key features of the study:
This report provides in-depth analysis of the global high potency active pharmaceutical ingredients market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021, as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
It profiles leading players in the global high potency active pharmaceutical ingredients market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Lonza, Novartis International AG, BASF AG, SEQENS, Carbogen Amcis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd Bristol-Myers Squibb, Pfizer Inc., Roche Diagnostics, Boehringer Ingelheim, Merck & Co, Bayer AG, Ajinomoto Bio-Pharma Molecule Types, Cambrex Corporation, Minakem, and Sanofi Aventis.
Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
The global high potency active pharmaceutical ingredients market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.
Detailed Segmentation
Global High Potency Active Pharmaceutical Ingredients Market, By Molecule Type:
Innovative
Generic
Global High Potency Active Pharmaceutical Ingredients Market, By Production Technology:
Chemical Synthesis
Biotechnology
Global High Potency Active Pharmaceutical Ingredients Market, By Application:
Oncology
Hormonal
Glaucoma
Others
Global High Potency Active Pharmaceutical Ingredients Market, By Geography:
North America
By Molecule Type
Innovative
Generic
By Production Technology
Chemical Synthesis
Biotechnology
By Application
Oncology
Hormonal
Glaucoma
Others
By Country:
U.S.
Canada
Europe
By Molecule Type
Innovative
Generic
By Production Technology
Chemical Synthesis
Biotechnology
By Application
Oncology
Hormonal
Glaucoma
Others
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
By Molecule Type
Innovative
Generic
By Production Technology
Chemical Synthesis
Biotechnology
By Application
Oncology
Hormonal
Glaucoma
Others
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
By Molecule Type
Innovative
Generic
By Production Technology
Chemical Synthesis
Biotechnology
By Application
Oncology
Hormonal
Glaucoma
Others
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Middle East:
By Molecule Type
Innovative
Generic
By Production Technology
Chemical Synthesis
Biotechnology
By Application
Oncology
Hormonal
Glaucoma
Others
By Country:
GCC
Israel
Rest of Middle East
Africa
By Molecule Type
Innovative
Generic
By Production Technology
Chemical Synthesis
Biotechnology
By Application
Oncology
Hormonal
Glaucoma
Others
By Country/Region:
Central Africa
South Africa
North Africa
Company Profiles
Lonza Inc.*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Novartis International AG
BASF AG
SEQENS
Carbogen Amcis AG
Eli Lilly and Company
Teva Pharmaceutical Industries Ltd
Bristol-Myers Squibb
Pfizer Inc.
Roche Diagnostics
Boehringer Ingelheim
Other Players
“*” marked represents similar segmentation in other categories in the respective section.